Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
PURPOSE: The purpose of this study was to compare the effects of filgrastim, sargramostim, or sequential sargramostim and filgrastim on CD34 + cell yields and morbidity after myelosuppressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results